Minutes of Pre-bid meeting for Procurement of HIV (ELISA), HBV(ELISA) & HCV(ELISA) TEST KITS against: IFB No. RITES/MSM/NACP/02/2015 held on 21/08/2015 at 14:00 hr at RITES office.

1. The following were present:-

I) From RITES
S/Shri
R K Sharma, JGM/MSM – In Chair
Manoj Kumar Das, Manger/MSM

II) Firms which attended the pre bid conference are as follows:

S. No.	Name of representative S/Shri	Name of Firm
1	J. K. Malhotra	M/s Transasia Biomedicals Ltd., New Delhi
2	Aldo M. P.	
3	Chander Prakash Kundra	M/s Alere Medical Pvt. Ltd., Gurgaon
4	Rajnish Roy	M/s Meril Diagnostics Pvt. Ltd., Mumbai
5	Subhash Kanti	

2. Initiating the discussion, chairperson welcomed the participants. It was explained that purpose of Pre-bid meet is to educate the bidders regarding various important provisions of the bidding documents and also to clarify any queries that the bidders may have in the subject bidding documents.

3. The issues raised during the pre bid meeting and clarifications are as under-

<table>
<tr><th>S. No.</th><th>Query Raised</th><th>Clarification</th></tr>
<tr><td></td><td>Section IV. Technical Specifications</td><td></td></tr>
<tr><td>1.</td><td>CDSCO guidelines for sensitivity and specificity of HIV, HBV and HCV ELISA kits for use in India is as given below. We request you to amend sensitivity and specificity limits given in your tender specifications as Elisa kits are approved and evaluated by NIB, Noida as per CDSCO guidelines only.
<table>
<tr><th>S. No.</th><th>Product Name</th><th>Tender specification</th><th>CDSCO guideline specificati</th><th>Amendment Required</th></tr>
<tr><td>1</td><td>HIV ELISA</td><td>Sensitivity: ≥99.8% Specificity: ≥98%</td><td>Sensitivity: ≥99.5% Specificity: ≥98%</td><td>Request for amending Sensitivit</td></tr>
<tr><td>2</td><td>HBsAg ELISA</td><td>Sensitivity: ≥99.8%, Specificity: ≥98%</td><td>Sensitivity: ≥99% (0.5 ng/ml) Specificity: ≥98%</td><td>Request for amending Sensitivity to</td></tr>
<tr><td>3</td><td>HCV ELISA</td><td>Sensitivity: ≥99.8% Specificity: ≥98%</td><td>Sensitivity: ≥99% Specificity: ≥98%</td><td>Request for amending Sensitivity to ≥99%</td></tr>
</table></td><td>There will be no change in this criteria</td></tr>
<tr><td>2.</td><td>As Per Sr. No 2 (ii) of Technical Specification “The cumulative time temperature indicator technology used</td><td>There will be no change in this criteria</td></tr>
</table>

S. No.	Query Raised	Clarification
	should be prequalified by WHO". Query: The Cold Chain being used by our company fulfills your Quality requirement i.e. "the maintenance of cold chain during storage & transport the kits at 28 degree Celsius". But the condition that time temperature indicator technology used should be prequalified by WHO has created a monopolistic situation and can restrict its usage. This results in increased prices and thereby having unfair competition. Hence, we would like to request you to kindly remove the condition of "**prequalified by WHO" and to make this IFB more competitive**.	
3.	Storage Temperature of ELISA KITS at District Hospitals & Blood Banks: General Query: During transportation from our factory warehouse to State AIDS Control Society Consignees we are maintaining cold chain of the kits at 28 degree Celsius. The same condition we want SACS to follow for storage and further transportation to their respective blood banks to avoid the deterioration and which results discrepancies as the components may get deteriorate out of this temperature range.	NACO has agreed for availability of Cold Chain facility at the consignee end and also during further transportation to blood banks.

Meeting concluded with thanks to the participants for their active participation.